{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:04:52Z","timestamp":1772759092880,"version":"3.50.1"},"reference-count":11,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,7,1]]},"abstract":"\n OBJECTIVE:<\/jats:title>\n Ten-valent pneumococcal conjugate vaccine (PCV10) was earlier shown to reduce clinically suspected, non\u2013laboratory-confirmed invasive pneumococcal disease (IPD) in a cluster-randomized trial (the Finnish Invasive Pneumococcal disease trial). PCV10 was introduced into the Finnish national vaccination program in September 2010 using a 3-dose schedule. We evaluated the impact of PCV10 on clinically suspected IPD among vaccine-eligible children in a population-based nationwide study.<\/jats:p>\n <\/jats:sec>\n \n METHODS:<\/jats:title>\n The target cohort eligible for vaccination program (children born June 2010\u2013September 2013) was compared with 2 season- and age-matched (ages 3\u201342 months) reference cohorts before PCV10 introduction. The trial period (January 2009\u2013August 2010) was excluded. Hospitals\u2019 inpatient and outpatient discharge notifications with International Classification of Diseases, 10th Revision, diagnoses compatible with IPD (A40.3\/B95.3\/G00.1\/M00.1) and unspecified sepsis (A40.9\/A41.9\/A49.9\/G00\/G00.9\/I30.1\/M00\/M00.9\/B95.5) were collected from the national Care Register. Laboratory-confirmed IPD cases were excluded. Rates of register-based non\u2013laboratory-confirmed IPD (or unspecified sepsis) before and after PCV10 implementation were calculated.<\/jats:p>\n <\/jats:sec>\n \n RESULTS:<\/jats:title>\n The rate of register-based non\u2013laboratory-confirmed IPD episodes was 32 in 100\u2009000 person-years in the vaccine-eligible target cohort and 94 in the combined reference cohorts. Relative rate reduction was 66% (95% confidence interval: 59\u201373) and absolute rate reduction 62 in 100\u2009000 person-years. For the more sensitive case definition of register-based non\u2013laboratory-confirmed IPD or unspecified sepsis, the relative rate reduction was 34% (95% confidence interval 29\u201339), but the absolute reduction was as high as 122 in 100\u2009000 person-years.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS:<\/jats:title>\n This is the first report demonstrating nationwide PCV impact on clinically suspected IPD during routine vaccination program. The large absolute rate reductions observed have major implications for cost-effectiveness of PCVs.<\/jats:p>\n <\/jats:sec>","DOI":"10.1542\/peds.2015-0458","type":"journal-article","created":{"date-parts":[[2015,6,16]],"date-time":"2015-06-16T00:42:25Z","timestamp":1434415345000},"page":"e22-e27","source":"Crossref","is-referenced-by-count":21,"title":["Pneumococcal Conjugate Vaccine and Clinically Suspected Invasive Pneumococcal Disease"],"prefix":"10.1542","volume":"136","author":[{"given":"Arto A.","family":"Palmu","sequence":"first","affiliation":[{"name":"Department of Health Protection, National Institute for Health and Welfare, Tampere, Finland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terhi M.","family":"Kilpi","sequence":"additional","affiliation":[{"name":"Department of Health Protection, National Institute for Health and Welfare, Helsinki, Finland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Rinta-Kokko","sequence":"additional","affiliation":[{"name":"Department of Health Protection, National Institute for Health and Welfare, Helsinki, Finland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Nohynek","sequence":"additional","affiliation":[{"name":"Department of Health Protection, National Institute for Health and Welfare, Helsinki, Finland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maija","family":"Toropainen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, National Institute for Health and Welfare, Helsinki, Finland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Pekka","family":"Nuorti","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, National Institute for Health and Welfare, Helsinki, Finland; and"},{"name":"Department of Epidemiology, School of Health Sciences, University of Tampere, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jukka","family":"Jokinen","sequence":"additional","affiliation":[{"name":"Department of Health Protection, National Institute for Health and Welfare, Helsinki, Finland;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2015,7,1]]},"reference":[{"issue":"3","key":"2021120820561035700_B1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00006454-200003000-00003","article-title":"Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children.","volume":"19","author":"Black","year":"2000","journal-title":"Pediatr Infect Dis J"},{"issue":"18","key":"2021120820561035700_B2","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","article-title":"Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.","volume":"348","author":"Whitney","year":"2003","journal-title":"N Engl J Med"},{"issue":"8","key":"2021120820561035700_B3","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/00365540801938931","article-title":"Trends and geographical variation in invasive pneumococcal infections in Finland.","volume":"40","author":"Klemets","year":"2008","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"2021120820561035700_B4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"issue":"3","key":"2021120820561035700_B5","doi-asserted-by":"crossref","first-page":"e0120290","DOI":"10.1371\/journal.pone.0120290","article-title":"Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in finnish children\u2014a population-based study.","volume":"10","author":"Jokinen","year":"2015","journal-title":"PLoS ONE"},{"issue":"9862","key":"2021120820561035700_B6","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0140-6736(12)61854-6","article-title":"Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.","volume":"381","author":"Palmu","year":"2013","journal-title":"Lancet"},{"issue":"9","key":"2021120820561035700_B7","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S2213-2600(14)70139-0","article-title":"Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial.","volume":"2","author":"Palmu","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"9930","key":"2021120820561035700_B8","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(13)61682-7","article-title":"Use of vaccines as probes to define disease burden.","volume":"383","author":"Feikin","year":"2014","journal-title":"Lancet"},{"issue":"10","key":"2021120820561035700_B9","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1473-3099(11)70090-1","article-title":"Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study.","volume":"11","author":"Miller","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2021120820561035700_B10","doi-asserted-by":"crossref","first-page":"e00309","DOI":"10.1128\/mBio.00309-10","article-title":"Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States.","volume":"2","author":"Simonsen","year":"2011","journal-title":"MBio"},{"issue":"5","key":"2021120820561035700_B11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(14)70032-3","article-title":"Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis.","volume":"2","author":"Simonsen","year":"2014","journal-title":"Lancet Respir Med"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/136\/1\/e22\/1094063\/peds_2015-0458.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/136\/1\/e22\/1094063\/peds_2015-0458.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T00:54:59Z","timestamp":1639011299000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/136\/1\/e22\/29065\/Pneumococcal-Conjugate-Vaccine-and-Clinically"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,1]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,7,1]]},"published-print":{"date-parts":[[2015,7,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2015-0458","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,1]]}}}